Comparing Micro-ultrasound and MRI for Prostate Cancer Screening
This study is comparing two imaging methods, microUltrasound (ExactVu) and standard prostate mpMRI, to see which is better at finding important prostate cancers. You might be able to join if you are a man between 50 and 70 years old, have a PSA (Prostate Specific Antigen, a blood test for prostate health) between 3-20, and/or an abnormal DRE (Digital Rectal Exam). You also shouldn't have had a prostate biopsy before. The study aims to find the most effective way to image the prostate to help decide if a biopsy is needed. Participants will be randomly assigned to receive either ExactVu or mpMRI.
- Study design
- This interventional study plans to enroll 1284 men. Participants will be randomly assigned to one of two groups to compare imaging results.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- After your imaging test, you will be followed for one year to see if clinically significant prostate cancer is detected.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
At a glance
Conditions
Where it's being run
9 sites across 9 statesStudy leadership
- Adam Kinnaird, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Alberta
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Detection of Clinically significant prostate cancer.Once enrolled, men will be followed for 1 year after the imaging test.
The primary objective of this trial is to determine if a screening pathway using microUS is non-inferior to a pathway using MRI for the detection of clinically significant prostate cancer, defined as Gleason Grade Group 2 or more.